Summary
AnswersNow has raised $40 million in Series B funding to scale its virtual Applied Behavioral Analysis (ABA) therapy platform, which utilizes **artificial intelligence** to create customized learning modules for children with autism. The company's approach has shown **clinically proven outcomes** in roughly one-sixth the therapy hours required by traditional in-person ABA, resulting in substantial savings for insurers and improved access for families. With this funding, AnswersNow plans to double its **BCBA workforce**, launch new service offerings, and continue investing in AI to further personalize care delivery. The company has already facilitated nearly **100,000 hours** of virtual ABA therapy and caregiver training in 2025, with **96%** of families reporting meaningful improvements in behavior and communication. For more information on autism therapy, visit [[autism-therapy|Autism Therapy]] and [[applied-behavioral-analysis|Applied Behavioral Analysis]].
Key Takeaways
- AnswersNow has raised $40 million in Series B funding to scale its virtual ABA therapy platform
- The company's approach has shown clinically proven outcomes in roughly one-sixth the therapy hours required by traditional in-person ABA
- AnswersNow facilitated nearly 100,000 hours of virtual ABA therapy and caregiver training in 2025
- The company plans to double its BCBA workforce and launch new service offerings
- The use of AI in autism therapy raises concerns about bias and accountability
Balanced Perspective
The Series B funding of AnswersNow is a significant development in the autism care space, but its impact will depend on various factors. While the company's AI-enabled platform has shown promising results, it is essential to consider the **complexities of autism** and the need for personalized care. AnswersNow's approach may not be suitable for all families, and the company will need to demonstrate the long-term efficacy and scalability of its model. Additionally, the **regulatory environment** and reimbursement landscape will play a crucial role in determining the company's success. To learn more about the regulatory environment, visit [[healthcare-regulation|Healthcare Regulation]].
Optimistic View
The funding of AnswersNow's AI-enabled, BCBA-led virtual autism therapy platform is a **game-changer** for families affected by autism. With its ability to deliver clinically proven outcomes in less time and at a lower cost than traditional models, AnswersNow is poised to revolutionize the autism care landscape. The company's use of **AI** to create customized learning modules is a significant innovation, and its commitment to publishing peer-reviewed research will help to establish the efficacy of its approach. As noted by **Sam Brasch**, partner at HealthQuest Capital, the current autism support system is broken, and AnswersNow's virtual therapy model aims to deliver results in less time and with lower costs than traditional therapy. For more information on the benefits of virtual therapy, visit [[virtual-therapy|Virtual Therapy]].
Critical View
Despite the funding, there are concerns about the **equity and accessibility** of AnswersNow's virtual therapy platform. The company's reliance on **Master's- and PhD-level BCBAs** may limit its ability to scale and reach underserved communities. Furthermore, the use of AI in autism therapy raises questions about **bias and accountability**, and the company will need to address these concerns to ensure the integrity of its platform. As the autism care landscape continues to evolve, it is essential to consider the potential **risks and limitations** of virtual therapy models. For more information on the risks and limitations, visit [[virtual-therapy-risks|Virtual Therapy Risks]].
Source
Originally reported by HLTH